The arrival of the Wegovy pill (semaglutide), the first oral GLP-1 drug approved to treat obesity, means freedom of choice: Adults who are looking to lose weight and have at least one weight-related ...

For developers using AI, “vibe coding” right now comes down to babysitting every action or risking letting the model run unchecked. Anthropic says its latest update to Claude aims to eliminate that ...

Diabetes hardware company embecta aims to look beyond insulin and reshape itself into a more varied drug delivery provider—and it’s kick-starting that effort with the acquisition of a global ...

Embecta, a company that develops diabetes management solutions, is moving into the auto-injection market with its latest planned acquisition. The Becton Dickinson & CO spinoff reported it would ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this ...

It took decades to develop the first treatments to address the root causes of Alzheimer’s disease, and when they first reached patients, they weren’t exactly convenient to take. Patients have to visit ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

"She was just laying there lifeless,” Melissa Melinder, whose daughter thought GLP-1s helped with stomachaches, said Cara Lynn Shultz is a writer-reporter at PEOPLE. Her work has previously appeared ...

(RTTNews) - Eisai Co., Ltd. (ESALY, ESALF, 4523.T) and Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has accepted for review Eisai's Supplemental Biologics License ...